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Abstract: Drug-eluting stents (DES) have had a major impact in interventional cardiology. 
Compared to bare metal stents, they significantly reduce restenosis and the need for target 
vessel revascularization. Four DES are available in the US, the first-generation sirolimus-
eluting (Cypher®) and paclitaxel-eluting (Taxus®) stents and later approved second-generation 
everolimus-eluting (Xience V®) and zotarolimus-eluting (Endeavor®) stents. The Xience V stent 
was approved on the basis of clinical efficacy and safety data from 3 studies in the SPIRIT 
clinical trial program. Within this trial series, the Xience V was superior to its bare metal stent 
counterpart, the Vision® stent, and noninferior to the paclitaxel-eluting stent for target vessel 
failure at 9 months. This review provides a comprehensive assessment of the data derived from 
both the pre- and post-approval randomized controlled trials and registry studies of Xience V 
that comprise the SPIRIT clinical trial program including recently published mid-term outcomes. 
The implications of the results in terms of interventional practice will be discussed.
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Introduction
Stenting is the default strategy in percutaneous coronary interventions due to 
superiority over balloon angioplasty in acute technical success and the subsequent 
need for target vessel revascularization. There are currently two broad categories of 
stents available: bare metal (BMS) and drug-eluting (DES). Bare-metal stents prevent 
coronary artery elastic recoil but restenosis may occur due to intimal hyperplasia. 
Drug-eluting stents are associated with a marked reduction in restenosis and target 
vessel revascularization compared to BMS.1,2 After the US approval of the first two 
DES, the sirolimus-eluting stent (Cypher®) in 2003 and paclitaxel-eluting stent 
(Taxus®) in 2004, concern was raised about the safety of the devices due to the occur-
rence of late and very late stent thrombosis. Pooled analyses of available randomized 
trails at the time, however, showed similar rates of death and myocardial infarction in 
patients treated with one of these DES compared to the BMS counterpart in random-
ized clinical trials.3 Registry studies also supported the safety of DES in unselected 
patients and off-label type lesions.4,5 Nonetheless, knowledge of delayed healing in 
DES and concern for stent thrombosis led to the recommendation to increase the 
duration of dual anti-platelet therapy with aspirin and clopidogrel in patients treated 
with a DES to 12 months.6 The sirolimus-eluting and paclitaxel-eluting DES are 
often referred to as the first-generation DES.Vascular Health and Risk Management 2009:5 1090
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More recently, two additional DES were approved in 
the US, the everolimus-eluting stent (Xience V®) in 2007 
and the zotarolimus-eluting stent (Endeavor®) in 2008. 
These two newer DES have similar basic components to the 
initially approved DES, with a stent platform, polymer and 
anti-restenotic drug. Due to advances in stent platforms, 
delivery systems and polymer biocompatibility coupled 
with the later time of approval, they are referred to as 
second-generation DES. These DES are designed from a 
cobalt–chromium alloy and are thinner and more flexible 
than the first-generation DES. In addition to advantages in 
deliverability, the second-generation DES may have superior 
long-term safety with similar or greater clinical efficacy. 
More head-to-head randomized controlled trials are needed, 
however, before conclusions can be made. The purpose of 
this review is to highlight the stent design and clinical trials 
that led to the approval of the everolimus-eluting stent, herein 
referred to as Xience V, and to provide a comprehensive 
update on the status of the SPIRIT clinical trial program. The 
timing of this review coincides with the release of mid-term 
study outcomes and the results will be discussed in relation 
to stent selection and patient outcomes.
Xience V stent design
The Xience V® Everolimus Eluting Coronary Stent System 
(Abbott Vascular, Santa Clara, CA, USA) is composed of a 
stent delivery system coated with a formulation containing 
the anti-restenotic drug everolimus embedded in a durable 
biocompatible polymer. The Xience V stent was approved by 
the US Food and Drug Administration (FDA) and launched 
in July 2008.7 The rationale for the design and polymer 
selection of the Xience V was the subject of a recent review.8 
In brief, the stent is the MULTI-LINK VISION Coronary 
Stent System which is manufactured from a medical grade 
cobalt–chromium alloy. The stent has favorable character-
istics such as a low profile and excellent deliverability that 
are due to a strut thickness of only 81 µm and an open cell 
non-linear link design. The stent delivery balloon is designed 
with a semi-compliant material (polyether block amide) with 
short tapers to prevent endothelial and vessel injury adjacent 
to the stented segment. The Xience V is contraindicated 
in patients with a hypersensitivity or adverse reaction to 
the components including: everolimus, cobalt, chromium, 
nickel, tungsten, acrylic and fluoropolymers.
Everolimus is the active pharmaceutical ingredient in the 
Xience V stent. It is a semi-synthetic macrolide immuno-
suppressant drug, synthesized by chemical modification of 
rapamycin (sirolimus). Everolimus is a proliferation signal 
inhibitor that acts on several cell types including vascular 
smooth muscle cells. The antiproliferative properties of the 
drug inhibit in-stent neointimal growth in experimental models 
and coronary vessels following stent implantation.9,10 At the 
cellular level, everolimus inhibits growth factor-stimulated 
cell proliferation. At the molecular level, everolimus forms 
a complex with the cytoplasmic protein FKBP-12 (FK 506 
Binding Protein). This complex binds to and interferes 
with FRAP (FKBP-12 rapamycin associated protein) also 
known as mTOR (mammalian target of rapamycin), leading 
to inhibition of cell metabolism, growth, and proliferation 
by arresting growth at the G1 stage.11 Everolimus is highly 
lipophilic, potent, and rapidly absorbed into tissue making 
it a desirable drug for intravascular delivery.
The Xience V stent contains the nonerodable polymer 
ingredients poly (n-butyl methacrylate) (PBMA), a polymer 
that adheres to the stent and drug coating (primer layer), 
and vinylidine fluoride and hexafluoropropylene monomers 
as the drug matrix layer containing everolimus (reservoir 
layer). The drug matrix copolymer is mixed with everolimus 
(83%/17% w/w polymer/everolimus ratio) and applied 
to the entire PBMA-coated stent surface. The drug load 
is 100 µg/cm2 for all stent sizes, for a nominal everoli-
mus content of 37 to 181 µg depending on the stent size. 
No topcoat layer is used. The copolymer elutes everolimus 
in a controlled fashion, 80% in 1 month and the remainder 
within 4 months.
Clinical studies
Safety and effectiveness data on the Xience V everolimus 
eluting stent (EES) is derived primarily from the SPIRIT 
Clinical Trial Program, which consists of 12 studies and 
will evaluate more than 18,000 patients. The initial studies, 
prior to FDA approval, were SPIRIT FIRST, SPIRIT II, and 
SPIRIT III. The SPIRIT III trials included three studies: 
the SPIRIT III randomized controlled trial versus Taxus, 
a registry of the 4.0 mm Xience, and the Japan Registry. 
The post-approval trials are in various stages of comple-
tion and include: SPIRIT IV, SPIRIT V, XIENCE V SPIRIT 
WOMEN, and post- approval registries XIENCE V USA, 
India, and EXCEED, and the small vessel investigational 
device exemption registry. For the purposes of this review, 
we will describe the most recent data publicly available 
regarding each of the SPIRIT trials as of the time of this 
writing. Additional selected studies, including COMPARE 
trial, will also be discussed. A summary of the randomized 
trials with primary endpoint data available is presented 
in Table 1.Vascular Health and Risk Management 2009:5 1091
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SPiRiT FiRST
The successful use of the Xience V EES was initially reported 
in the SPIRIT FIRST trial. This prospective, single-blinded, 
randomized, multicenter trial conducted in European evalu-
ated the safety and efficacy of the Xience V versus an iden-
tical Multi-Link Vision bare metal stent in the treatment 
of patients with a single de novo coronary artery stenosis 
of 50% and 100% and a vessel diameter of 3.0 mm as 
assessed by on-line quantitative coronary angiography that 
could be covered by a single 18 mm stent. Dual antiplatelet 
therapy was recommended for three months. The primary 
endpoint of the study was in-stent late lumen loss at 6 months 
by quantitative coronary angiography. Sixty patients were 
randomized and at 2-year follow-up, clinical data were 
available in 96% and 97% of patients in the everolimus 
and control arm, respectively. Four patients were excluded 
due to protocol violations and 2 patients withdrew consent. 
The mean in-stent late loss was significantly lower in the 
everolimus group (0.10 mm versus 0.87 mm, P  0.001) 
as was neointimal hyperplasia as assessed by intravascular 
ultrasound (IVUS).12
The SPIRIT FIRST trial was not powered for clinical 
endpoints; however, the 1-year major adverse cardiac event 
(MACE) rate was 15.4% in the everolimus arm and 21.4% 
in the bare stent arm.13 At 2 years the MACE rate for the 
everolimus arm remained 15.4%, but 2 patients in the control 
arm had target lesion revascularization for an overall MACE 
rate of 25.0%.14 Under the Dublin/Academic Research 
Consortium (ARC) definition of late stent thrombosis, there 
were zero late stent thromboses in the Xience V arm of the 
SPIRIT FIRST Trial up to 3 years of clinical follow-up. 
Unpublished 5-year follow-up data from SPIRIT FIRST 
presented by Eberhard Grube, MD at EuroPCR May 21, 2009 
indicate no additional MACE since 1-year follow-up in the 
Xience V group. Data from this trial and extended follow-up 
confirm the safety and efficacy of Xience V EES compared 
to the BMS platform.
SPiRiT ii
SPIRIT II is a 300-patient randomized, single-blind, prospec-
tive clinical trial evaluating the Xience V EES versus the 
Taxus Paclitaxel-Eluting Coronary Stent System (TAXUS 
EXPRESS2 or Liberté, Boston Scientific, Nadic, MA) (PES) 
in Europe and Asia Pacific. Patients with de novo coronary 
artery lesions of  50% to 99% stenosis and demonstrated 
ischemia were randomized 3 to 1 to receive either the Xience V 
(n = 223) or a Taxus (n = 77) stent. The primary endpoint 
of SPIRIT II was in-stent late loss at 180 days. Percentage 
in-stent volume obstruction was obtained by IVUS in a 
subset of 152 patients, who also underwent serial angio-
graphic follow-up at 6 months and 2 years. At 6 months, 
the in-stent late loss was significantly lower in the Xience V 
Table 1 Randomized clinical trials of the Xience V everolimus eluting stent
Study (reference) Design Primary endpoint Results
SPiRiT i N = 6012 Prospective, multicenter 
RCT versus Vision bare 
metal stent
in-stent LL at 
6 months
In-stent LL was significantly lower in the 
Xience group versus Vision (0.10 mm versus 
0.87 mm, P  0.001)
SPiRiT ii N = 30015 Prospective, multicenter 
RCT versus Taxus PeS
in-stent LL at 180 days In-stent LL was significantly lower in the 
Xience arm versus Taxus (0.11 ± 0.27 mm 
versus 0.36 ± 0.39 mm, P  0.0001)
SPiRiT iii N = 100219 Prospective, multicenter 
RCT versus Taxus PeS
in-segment LL at 
8 months
in-segment LL was lower in the Xience V 
group versus Taxus (0.14 mm versus 0.28 mm, 
P  0.001 for noninferiority and P = 0.004 
for superiority)
SPiRiT iV N = 3687* Prospective, multicenter 
RCT versus Taxus PeS
ischemia-driven target 
vessel failure (cardiac 
death, target vessel Mi, 
ischemia driven TLR) 
at 1 year
Target lesion failure was significantly lower in 
the Xience V arm versus Taxus (4.2% versus 
6.8%, HR 0.62, 95% Ci 0.46–0.82, P = 0.001 
for superiority)
COMPARe trial N = 1800** Prospective, single-center, 
RCT versus Taxus PeS in 
unselected patients
Death, Mi and target 
vessel revascularization 
at 12 months
Primary endpoint was significantly lower in 
the Xience group versus Taxus (6.2% versus 
9.1%, RR 0.69 0.5–0.95, P = 0.023)
*1-year results were presented by Dr Gregg Stone at the Transcatheter Cardiovascular Therapeutics Meeting (September 2009, San Francisco, CA).
**1-year results were presented by Dr Peter C. Smits at the Transcatheter Cardiovascular Therapeutics Meeting (September 2009, San Francisco, CA).
Abbreviations: CI, confidence interval; HR, hazard ratio; RCT, randomized controlled trial; RR, relative risk; LL, late loss; PES, paclitaxel-eluting stent; MI, myocardial infarction; 
TLR, target lesion revascularization.Vascular Health and Risk Management 2009:5 1092
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arm compared to the Taxus arm (0.11 ± 0.27 mm versus 
0.36 ± 0.39 mm, P  0.0001). Percentage volume obstruc-
tion in the Xience V arm was also significantly lower. 
Thus, Xience V met the primary endpoint and was found 
to be superior to Taxus with respect to late loss. Clinical 
secondary endpoints in SPIRIT II included ischemia driven 
MACE and rates were non-significantly different at 2.7% 
(6/222) in the Xience V arm and 6.5% (5/77) in the Taxus 
arm.15 Although not a primary endpoint, 1-year clinical 
follow-up results demonstrated lower rates of MACE for 
Xience V compared to Taxus (2.7% versus 9.2%, P = 0.04). 
As defined in SPIRIT II, the MACE rate included death, 
myocardial infarction (MI) or clinically driven target lesion 
revascularizations. Under the ARC definition, the late-stent 
thrombosis rate up to 1 year was 0% with Xience V and 
1.3% for Taxus.16 In a post-hoc analysis of  SPIRIT II angio-
graphic outcomes in high-risk patients including those with 
diabetes, left anterior descending artery lesions, lesions 
longer that 20 mm, vessels smaller than 3.0 mm and 
type B2 and C lesions, the in-stent late loss results were 
consistent with the findings in the overall SPIRIT II trial 
population.17 In all, the primary outcome and 1-year clinical 
data favored Xience V.
Recently, 2-year clinical, angiographic, and IVUS 
follow-up of patients in the SPIRIT II trial was published.18 
After 2 years, target lesion failure defined as cardiac death, 
MI, and ischemia-driven target lesion revascularization rates 
were numerically but not statistically lower at 6.6% in the 
Xience V group and 11% in the Taxus group respectively 
(P = 0.31). Additionally, in the 115 patients with serial 
angiography, the initial 6-month benefit of Xience V over 
Taxus in terms of in-stent late loss (Xience V 0.33 ± 0.37 mm 
versus Taxus 0.34 ± 0.34 mm, P = 0.84) and percent volume 
obstruction (5.18 ± 6.22% versus 5.80 ± 6.31%, P = 0.65) 
was lost at 2 years. The incidence of stent thrombosis was 
low and similar in both groups (Xience V 0.9%, Taxus 
1.4%). Therefore, at two-year follow-up in SPIRIT II, there 
were no significant differences between Xience V and Taxus 
in clinical, angiographic, and IVUS outcomes. The findings 
confirm, however, that Xience V is noninferior to Taxus 
for late loss at 2 years.
SPiRiT iii
SPIRIT III is a randomized clinical trial comparing the 
Xience V to the Taxus stent system in 1,002 patients in 
the United States and Japan. Patients were randomized 
2:1 to Xience V (n = 669) or Taxus (n = 333). A subset 
of patients underwent repeat angiographic follow-up 
at 8 months (n = 564), some of whom also had IVUS. 
Lesion location was the left anterior descending in 42% 
of patients. The baseline angiographic characteristics 
were well matched in terms of reference vessel diameter, 
lesion length, and the mean number of stents per patient. 
The primary endpoint of in-segment late lumen loss 
at 8 months was lower in the Xience V group than the 
Taxus group (0.14 mm versus 0.28 mm, P  0.001 for 
noninferiority and P = 0.004 for superiority). In-segment 
binary restenosis occurred in 4.7% of the EES group and 
8.9% of the PES group (P = 0.07). On IVUS, neointimal 
hyperplasia volume was lower in the Xience V compared 
to the Taxus group (10.1 mm3 versus 20.9 mm3, P = 0.04). 
There was no difference in the major secondary endpoint 
of target vessel failure at 9 months (7.2% Xience V versus 
9.0% Taxus; P  0.001 for noninferiority and P = 0.31 
for superiority). The Xience V did, however, reduce the 
risk of MACE at 9 months (4.6% versus 8.1%; relative 
risk, 0.56 [95% confidence interval (CI), 0.34 to 0.94]; 
P = 0.03) and 1 year compared to Taxus (6.0% versus 
10.3%; relative risk, 0.58 [95% CI, 0.37 to 0.90]; P = 0.02), 
with fewer MIs and target lesion revascularizations. Stent 
thrombosis occurred in 0.8% of the Xience V group and 
0.6% of the Taxus group (P  0.99).19
In SPIRIT III at 2 years, the individual outcomes of 
cardiac death occurred in 1.1% and 1.3% (P = 0.75), 
MI in 3.3% and 5.9% (P = 0.08), target lesion revascular-
ization occurred in 6.1% and 11.3% (P = 0.006), and target 
vessel failure occurred in 11.3% and 16.4% (P = 0.04), 
respectively for Xience V versus Taxus. MACE defined 
as cardiac death, MI, or target lesion revascularization 
occurred in 7.7% and 13.8% (P = 0.005), respectively 
for Xience V and Taxus. Cumulative stent thrombosis at 
2 years occurred in 1.0% and 1.7% (P = 0.35), whereas 
very late thromboses (1 to 2 years) occurred in 0.2% 
and 1.0% (P = 0.10), respectively, for Xience V and Taxus. 
Among 360 patients who discontinued dual antiplatelet 
therapy after 6 months there were numerically fewer stent 
thrombosis events in Xience V-treated patients compared 
to Taxus (0.4% versus 2.6%, P = 0.10).20 A pooled analysis 
of the 2-year follow-up of SPIRIT II and III confirmed 
these findings.21
The three year SPIRIT III results were presented at 
the Transcatheter Cardiovascular Therapeutics Meeting 
(San Francisco, CA, September 2009) by Dr Gregg Stone 
and further support the Xience V EES. Similar to the 2-year 
results, target vessel failure, target lesion revascularization, 
and MACE were all significantly lower in the Xience V group Vascular Health and Risk Management 2009:5 1093
Review of the SPiRiT clinical trial program Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
versus Taxus group. In the subgroup of patient with diabetes 
mellitus, however, no difference in outcomes was observed 
between Xience V and Taxus.
There were two small registries that enrolled con-
currently with the SPIRIT III randomized trial, the 
SPIRIT III 4.0 Registry and SPIRIT Japan. The SPIRIT III 
4.0 Registry consisted of  69 nonrandomized patients with 
lesions 28 mm in length and reference vessel diameter 
3.75 to 4.25 mm treated with a 4.0 mm Xience V . In-segment 
late loss was 0.17 ± 0.38 mm and similar to the randomized 
Xience V cohort. In-segment binary angiographic restenosis 
at 240 days occurred in only 1 patient receiving a 4.0 mm 
Xience V (2.0%). Ischemia-driven target vessel failure at 
1 year occurred 5.9% of patients in the 4.0 mm Xience V 
cohort. The SPIRIT III 4.0 Registry is one of the few studies 
evaluating outcomes for de novo lesions 3.75 mm in 
diameter treated with DES.22 The SPIRIT III Japan is a 
prospective, multicenter, nonrandomized arm using EES 
in Japan. IVUS of 79 Japan patients at 8 months follow-up 
was compared to 115 Xience V and 45 Taxus patients in 
the randomized SPIRIT III trial. Significant suppression 
of neointimal hyperplasia in the Japanese population was 
observed demonstrating the effectiveness of the Xience V 
stent in this population.23
SPiRiT iV
SPIRIT IV is an ongoing, prospective, 3687-patient, post-
approval trial evaluating the safety and efficacy of the 
Xience V stent system for the treatment of coronary artery 
disease in a more complex patient population. Similar to 
the SPIRIT II and III trials, this large-scale randomized trial 
will further assess the differences between the Xience V 
and Taxus platforms. The details of the trial design were 
recently published.24 This single-blinded, randomized, 
multicenter US study will randomize patients with up 
to 3 de novo native coronary artery lesions, with a maximum 
of 2 lesions per vessel to Xience V or Taxus in a 2:1 fashion. 
The primary endpoint of the trial is ischemia-driven target 
vessel failure (cardiac death, target vessel MI, ischemia-
driven TLR) at 1 year and patients will be followed out to 
5 years. The trial is powered for sequential noninferiority 
and superiority testing. The absence of routine angiographic 
follow-up in this trial may allow a more accurate assessment 
of the absolute differences in the clinical safety and efficacy 
profile between Taxus and Xience V. The number of patients 
in the trial may also permit insights into the relative perfor-
mance of the 2 stents in subgroups of patients including those 
with diabetes mellitus.
SPIRIT IV enrollment began in August 2006 and the 
1-year results were presented by Dr Gregg Stone at the Trans-
catheter Cardiovascular Therapeutics Meeting (September 
2009, San Francisco, CA); publication of results in the 
peer-reviewed medical literature is presently awaited. A total 
of 2458 were randomized to Xience V and 1229 to Taxus. 
Baseline characteristics were similar between the two groups, 
with a mean patient age of 63.3 years and 32% female. 
Approximately 32% of patients were diabetics, including 
9% insulin-dependent. About 21% had prior myocardial 
infarction and 28% presented with unstable angina pectoris. 
The mean reference vessel diameter was 2.75 mm, lesion 
length 14.7 mm, and stented length per lesion was about 
22 mm. The primary endpoint of target lesion failure was 
significantly lower in the Xience V arm compared with the 
Taxus arm (4.2% versus 6.8%, hazard ratio [HR] 0.62, 95% 
CI, 0.46 to 0.82, P = 0.001 for superiority). This was driven 
primarily by a significant reduction in ischemia-driven TLR 
(2.5% versus 4.6%, HR 0.55, 95% CI 0.38 to 0.78, P = 0.001). 
Cardiac death or target vessel MI were similar between the 
two arms (2.2% versus 3.2%, P = 0.09). All-cause mortality 
was similar (1.0% versus 1.3%, P = 0.61), but Xience was 
associated with a significant reduction in MI (1.9% versus 
3.1%, P = 0.05). In addition, Xience was associated with a 
significant reduction in stent thrombosis at 1 year, as com-
pared with Taxus (0.29% versus 1.06%, HR 0.27, 95% CI 
0.11 to 0.67, P = 0.003). In the subset of patients with diabetes 
mellitus, however, no difference in MI, target lesion revas-
cularization or the composite endpoints of MACE and target 
vessel failure was observed between Xience V and Taxus.
SPiRiT V
SPIRIT V is an international post-approval trial that will 
provide additional clinical experience with Xience V in 
approximately 2663 patients at approximately 100 sites 
clinical sites throughout Europe, Asia, Canada and Latin 
America. The SPIRIT V Clinical Evaluation consists of two 
concurrent studies, the Diabetic Study and the Registry. 
The SPIRIT V Diabetic Study is a prospective, randomized, 
active-controlled, single-blind, parallel two-arm multicenter 
study comparing the Xience V to the Taxus Liberté in the 
treatment of diabetic patients with coronary artery lesions, 
and the SPIRIT V Registry, a prospective, single arm, 
multicenter registry evaluating performance of the Xience 
V in real-world clinical settings, per its instruction for use. 
The trial is currently enrolling patients. Real-world clinical 
settings may include up to 4 planned Xience V stents in 
de novo target lesions with a reference diameter between Vascular Health and Risk Management 2009:5 1094
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2.5 and 4 mm and a lesion length less than or equal to 28 mm. 
Enrolled patients will be followed for 5 years and clopidogrel 
is recommended for at least 3 months. Initial results were 
presented at the EuroPCR Meeting by Prof. Eberhard Grube 
(May 21, 2009, Barcelona, Spain). The 1-year rates of target 
lesion revascularization, definite/probable stent thrombosis, 
and MACE were 1.8%, 0.7%, and 5.1% respectively. The 
results suggest that Xience V is safe and effective in more 
complex patient and lesion subsets than were examined in 
the pre-approval trials.
XieNCe V SPiRiT wOMeN
The XIENCE V SPIRIT WOMEN trial will evaluate the 
characteristics of 2000 women undergoing stent implanta-
tion as well as the performance of Xience V in those patients 
in Europe, Asia-Pacific, Canada, and Latin America. The 
study, which is currently enrolling, will evaluate patient 
and disease characteristics specific to women as well as treat-
ment outcomes such as rate of death, MI and target vessel 
revascularization and potential risk of stent thrombosis.
Additional post-approval registries 
and trials
XIENCE V USA is a 5000-patient, prospective, open-label, 
multicenter (108 sites in the US); observational, single-
arm registry designed to evaluate continued safety and 
efficacy of the Xience V stent in real world settings, and 
will evaluate outcomes such as late stent thrombosis, death, 
MI and revascularization with follow-up out to 5 years. 
Primary outcome measures include: stent thrombosis rates as 
defined by ARC annually through 5 years and the composite 
endpoint of cardiac death and MI at 1 year. The study also 
will evaluate patient compliance with antiplatelet therapy. 
The study started in July 2008, with final data collection 
for the primary outcome measures expected in June 2009 
(clinicaltrials.gov). Data from the XIENCE V USA Registry 
are presently awaited.
XIENCE V India is a 1000-patient, prospective, open-
label, multicenter (16 sites in India), observational, single-
arm registry to evaluate Xience V continued safety and 
effectiveness during commercial use in real world settings, 
with follow-up planned through 5 years. Primary outcome 
measures include: stent thrombosis rates as defined by 
ARC annually through 5 years and the composite endpoint 
of cardiac death and myocardial infarction at one year. 
XIENCE V India follow-up will document patient adher-
ence and persistence with adjunctive antiplatelet drug 
therapy at several time points throughout the study. The 
study started in June 2008, is expected to be completed 
in June 2013, with final data collection for the pri-
mary outcomes expected to be completed in June 2010 
(clinicaltrials.gov).
XIENCE V EXCEED (Evaluation of Xience V Cath-
eterization Lab Endpoints and Excellence in Delivery) is 
a 2517-patient, observational, prospective, multicenter 
(44 sites in the US) cohort study designed to assess physician-
determined Xience V acute performance, deliverability and 
resource utilization in the catheterization lab during com-
mercial use by various physicians with a range of coronary 
stenting experience. The study started in October 2008, 
with estimated completion in March 2010, with final data 
collection for primary outcome in March 2009 and data are 
presently awaited (clinicaltrials.gov).
SPIRIT Small Vessel trial is designed to study the use of 
a 2.25 mm Xience V stent in 250 patients at approximately 
50 centers in the United States. The primary endpoint is 
a composite measure of cardiac death, MI and TLR at 
one year.
COMPARe trial
The COMPARE trial is a physician-initiated, single center, 
prospective, randomized trial comparing the Taxus Liberte 
against the Xience V EES in an all-comer real-world popu-
lation. The study enrolled 1800 patients and used a 1:1 ran-
domization to Taxus Liberte (n = 903) or Xience V (n = 897) 
with the operator blinded to stent type. The 1-year results 
were presented by Dr Peter C. Smits at the Transcatheter 
Cardiovascular Therapeutics Meeting (September 2009, 
San Francisco, CA). The groups were well-matched relative 
to baseline variables and approximately 60% of patients 
presented with an acute coronary syndrome. The primary 
endpoint of death, MI and TVR at 12 months was observed 
in 9.1% of patients in the Taxus group and 6.2% in the 
Xience V group (relative risk 0.69 [0.5 to 0.95], P = 0.023). 
Secondary endpoints of MACE, ARC definite and probable 
stent thrombosis, and nonfatal MI were also statistically 
significantly lower the Xience V group. Longer follow-up 
is not yet available.
Next generation Xience
The XIENCE Prime EES System is the next generation 
Xience stent. The XIENCE Prime stent, currently an 
investigational device, uses the same drug and polymer as 
Xience V; however the stent design and delivery system 
have been modified to improve flexibility and deliverability. 
Similar to Xience V , the stent will be cobalt chromium and Vascular Health and Risk Management 2009:5 1095
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the design based on the MULTI-LINK family of stents. 
The XIENCE Prime will be evaluated in the SPIRIT Prime 
study, a prospective, multicenter, nonrandomized trial of 
500 patients at 75 hospital centers. SPIRIT Prime will have 
2 arms: the Core arm will follow 400 patients who will be 
treated with a stent from 2.25 mm to 4.0 mm in diameter 
and from 8 mm to 28 mm in length, and the Long Lesion 
arm will follow 100 patients who will receive a stent from 
2.5 mm to 4.0 mm in diameter and either 33 mm or 38 mm 
in length. The primary endpoint is MACE and TLR at one 
year. The recently announced EXCEL trial, a randomized 
trial of CABG versus DES in 2500 patients with left main 
disease, will also use the XIENCE Prime stent.
Clinical implications of the SPIRIT 
clinical  trial program
The Xience V EES is a second-generation DES that is 
effective at inhibiting neointimal hyperplasia, with less 
late loss compared to its BMS equivalent the Vision stent. 
The stent has favorable characteristics such as a deliverable 
cobalt–chromium stent platform and the lipophilic antip-
roliferative drug everolimus, which is completely released 
from a durable reservoir polymer over several months. 
In the US, the Xience V was the third DES to be approved, 
after the first-generation Cypher and Taxus DES, and prior 
to the Endeavor DES. Each DES differs in stent platform, 
drug, and polymer, which may result in differences in stent 
performance in terms of efficacy in preventing intimal 
hyperplasia and safety from stent thrombosis due to delayed 
healing. Substantive comparative data, however, among the 
four DES are lacking.
The SPIRIT program evaluated Xience V compared to 
Taxus in a series of studies. In patients with simple lesions 
and low-risk profiles, the Xience V results in reduced late 
loss at 6 to 8 months and noninferior rates of 9-month target 
vessel failure compared to the Taxus. A catch up phenom-
enon, with similar rates of late loss at 2 years, however, was 
noted in subset of SPIRIT II patients that underwent serial 
angiography. Despite these findings, a reduction in clinical 
events was observed with Xience V in SPIRIT III, including 
significantly lower rates of target lesion revascularization 
and MACE. The benefits of EES may, to some degree, have 
been influenced by protocol driven routine angiographic 
follow-up. The preliminary results of SPRITI IV support 
the clinical benefits of Xience V compared to Taxus in 
higher-risk patient and lesion subsets; however, these 
benefits do not appear to extend to patients with diabetes 
mellitus. The findings of the COMPARE trial suggest an 
even greater benefit of  Xience V compared to Taxus when 
used in unselected patients with potentially more complex 
lesion types than examined in the SPIRIT trials. Longer 
follow-up is needed to determine if the initial benefits seen 
with Xience V will persist.
In terms of safety, the SPIRIT studies were not powered 
to detect differences in rare events such as stent throm-
bosis, but mortality was similar and MI rates similar or 
lower in Xience compared to Taxus. Although the rates of 
stent thrombosis were numerically lower in the Xience V 
patients, the relative safety compared to Taxus in patients 
on or off dual anti-platelet therapy is not certain. The low 
rates of late and very late stent thrombosis with Xience are 
encouraging. Pre-clinical studies of stent healing suggest 
that endothelialization, a surrogate for stent thrombosis risk, 
is more rapid with Xience than the other 3 DES but that 
by 28 days strut coverage is similar.25
The Xience V Stent Evaluated at Rotterdam Cardiac 
Hospital (X-SEARCH) registry is a single-center registry 
of 649 consecutive patients treated with EES. Patients 
treated with EES were compared with patients who were 
treated in the past with BMS, SES (RESEARCH registry) 
and PES (T-SEARCH registry). In this registry, patients 
treated with EES were older; more often had MI, and had 
more complicated lesions compared to the other groups. 
At 6 months, after adjustment, EES was superior to BMS for 
target vessel revascularization and MACE, and had similar 
clinical outcomes to SES. Similar to the SPIRIT trials, PES 
had a higher risk of MACE compared to EES, extending 
the findings to a high risk, all-comers population.26
Currently, no randomized trials are comparing the Xience V 
to the other FDA-approved DES, the Cypher or Endeavor. 
The RESOLUTE-III trial was designed to compare the 
Endeavor-Resolute Zotarolimus-Eluting stent system with 
the XIENCE V EES system with respect to cardiac death, 
MI, and TLR at 1 year in a real-world patient population. 
The study started in April 2008 and is a prospective, 
multicenter, randomized, two-arm, international, noninfe-
riority, open-label study with 2300 patients. The Principal 
Investigator is Dr Patrick Serruys and final data collection 
for the primary outcome measure is expected in May 2010 
(clinicaltrials.gov). The clinical results of the Xience V 
versus the Cypher sirolimus-eluting stent were evaluated 
by means of an indirect comparison meta-analysis. Using 
this analytical method, the Xience V was found to be at 
least as effective as Cypher in preventing TLR (P = 0.12).27 
Whether this will hold true in a randomized study will 
be determined by future trials. The study design and Vascular Health and Risk Management 2009:5 1096
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rationale for a randomized trial comparing the Xience V 
to the Cypher was recently published. The Efficacy of 
Xience/Promus versus Cypher in rEducing Late Loss after 
stENTing (EXCELLENT) trial will prospectively enroll 
1,400 patients. In addition to comparing EES versus SES, 
using a 2 × 2 factorial design, this study will also address 
the issue of a 6- versus 12-month duration of dual anti-
platelet therapy.28
Conclusions
In sum, the results of the SPIRIT family of trials published 
to date suggest both excellent safety, and improved efficacy 
of the Xience V EES compared to both the MULTI-LINK 
VISION bare metal stent and the Taxus PES. Indirect data 
suggest that the Xience V is comparable to the Cypher 
but final comments await the planned randomized trial. 
The RESOLUTE III study comparing the Xience V to 
the other second-generation DES, Endeavor, is eagerly 
awaited. Lastly, with rapidly evolving DES technology, 
second-generation DES including Xience V will need to 
be compared to stents such as the BioMatrix and Norobi. 
These third-generation devices combine a bioresorbable 
polymer with an analogue of sirolimus, Biolimus A9, and 
preliminary results evaluating the inhibition of neointimal 
tissue are favorable.
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